Loreto G.
- Country
- Italy
- Department
- UOC Nefrologia, Dialisi e Trapianto
Research Overview
- Efficacy and Safety of Oral BI 764198 in Adults and Adolescents with Primary or TRPC6-Variant Genetic Focal Segmental Glomerulosclerosis: A Randomized, Placebo-Controlled Trial
- Long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy: an open-label extension study
- Phase II Basket Trial of BI 764198 in Adults and Adolescents With Proteinuric Kidney Diseases
Data & Insights
Has run more than one trial at 214 of 530 partner sites.
Specializations
Primary Glomerular Disorders
This investigator specializes in treating primary glomerular diseases, with particular focus on IgA nephropathy and focal segmental glomerulosclerosis. Their research encompasses innovative therapeutic approaches for managing these conditions.
- Primary Membranous Nephropathy
- Focal Segmental Glomerulosclerosis (FSGS)
- IgA Nephropathy
The investigator evaluates novel treatments targeting proteinuria reduction and renal function preservation in these conditions.
Autoimmune Kidney Disorders
Their expertise extends to autoimmune-related kidney conditions, particularly focusing on lupus nephritis and immune complex-mediated disorders.
- Lupus Nephritis
- Immune Complex Mediated Membranoproliferative Glomerulonephritis
The research focuses on evaluating targeted therapies for managing immune-mediated kidney diseases.
Advanced Kidney Disease Management
The investigator studies treatments for chronic kidney disease and end-stage kidney disease, including innovative dialysis solutions and therapeutic approaches.
- Chronic Kidney Disease with Albuminuria
- End-Stage Kidney Disease
- Peritoneal Dialysis Innovations
Their work includes evaluation of novel therapeutic combinations and alternative treatment strategies for advanced kidney conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.